Photoactivatable Cancer Prodrug Photoactivatable Ruthenium Compounds for Cancer Treatment

Description:

This technology introduces a new class of photoactivatable compounds based on ruthenium for the treatment of cancer. Leveraging the principles of photodynamic therapy (PDT), these compounds are designed to be activated by light to target and disrupt cancer cells selectively, while sparing healthy tissues. This innovative approach aims to overcome the limitations of traditional chemotherapy and improve the efficacy and safety of cancer treatment.

Key Advantages:

• Minimally invasive treatment with precise spatial accuracy.
• Reduces systemic side effects by targeting only cancer cells.
• Effective against various types of cancers, including those resistant to other forms of therapy.
• Utilizes light activation, allowing for controlled treatment and reduced toxicity.
• Potentially effective in treating cancers with poor oxygenation, where traditional PDT is less effective.

Problems Solved:

• Systemic toxicity associated with conventional chemotherapy.
• Limitations of current PDT due to oxygen dependency and poor tissue oxygenation.
• Resistance of certain cancers to existing microtubule-targeting agents.
• Need for more effective treatments for multidrug-resistant cancers.

Market Applications:

• Treatment of a wide range of cancers, including skin, lung, gastrointestinal, prostate, head and neck, brain, bile duct, bladder, and esophageal cancers.
• Development of new chemotherapy drugs with reduced side effects.
• Advancements in photodynamic therapy techniques and equipment.
• Research tools for studying cancer cell biology and drug interactions.